Amit G. Singal

Hepatology · 2009–2023

A researcher in the Science corpus: 11 papers; trusts 10 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 180 citations into it
• Epidemiology — 129 citations into it
• Statistics and Probability — 17 citations into it
• General Health Professions — 9 citations into it

Whom Amit G. Singal trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Jordi Bruix1 , 2
2. J. Llovet
3. H. B. EL‐SERAG
4. Riccardo Lencioni
5. David Moher
6. A. Cheng
7. Julian P. T. Higgins
8. Merrick Zwarenstein
9. R. Finn
10. J. Ferlay

Who trusts Amit G. Singal overall

1. J. Heimbach
2. L. Kulik
3. seung-ku nam

Papers from Amit G. Singal's perspective

Ordered by how strongly the researchers Amit G. Singal trusts endorse each paper. Same corpus, a different order for every researcher.

1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
3. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (Cardiovascular and Interventional Radiology)
4. Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
5. Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis (Alimentary Pharmacology and Therapeutics)
6. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
7. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
8. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma (Gastroenterology)
9. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. (Gastroenterology)
10. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis (Gut)

Their papers

• AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023) — 1,275 citations
• Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023) — 771 citations
• BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. (2021) — 2,982 citations
• Epidemiology and Surveillance for Hepatocellular Carcinoma: New Trends (2020) — 976 citations
• Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis (2019) — 970 citations
• Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis (2018) — 1,051 citations
• Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. (2018) — 1,031 citations
• Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study (2017) — 721 citations
• A Primer on Effectiveness and Efficacy Trials (2014) — 664 citations
• Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis (2014) — 740 citations
• Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis (2009) — 789 citations